Although Agios and Celgene are set to file for approval for their first-in-class cancer metabolism drug, the field has started looking in new directions for the next batch of metabolic targets.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Regulatory pathways and drugs associated with ferroptosis in tumors
Cell Death & Disease Open Access 10 June 2022
-
TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress
Communications Biology Open Access 09 June 2022
-
How previous treatment changes the metabolomic profile in patients with metastatic breast cancer
Archives of Gynecology and Obstetrics Open Access 25 April 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. Cancer metabolism pipeline breaks new ground. Nat Rev Drug Discov 15, 735–737 (2016). https://doi.org/10.1038/nrd.2016.223
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.223
This article is cited by
-
Modeling and Simulation in Biomedical Engineering: Regulatory Science and Innovation for Advancing Public Health
Annals of Biomedical Engineering (2023)
-
Regulatory pathways and drugs associated with ferroptosis in tumors
Cell Death & Disease (2022)
-
TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress
Communications Biology (2022)
-
How previous treatment changes the metabolomic profile in patients with metastatic breast cancer
Archives of Gynecology and Obstetrics (2022)
-
Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers
Journal of Experimental & Clinical Cancer Research (2021)